Liraglutide vs Dulaglutide China Supplier Guide

Create separate molecular and production specifications

Write independent RFQ lines with each full name, molecular or sequence reference, modifications or conjugated features where applicable, production-route expectations, form, target quality criteria, strength and RUO status. The supplier should identify the manufacturing, testing, filling and release parties for the exact product. A broad GLP-1 label does not authorize substitution. Require the quote, COA, analytical files, labels and packing list to map consistently to the buyer-approved Liraglutide or Dulaglutide specification.

Compare overlapping and unique strengths

List Liraglutide 5mg, 10mg and 30mg and Dulaglutide 5mg and 10mg on separate rows. Record vials, kits, total nominal material, content tolerance, parent lot, finished lot and price basis. The shared 5mg and 10mg labels increase mixed-order swap risk. Ask how multiple strengths are filled and reconciled and prohibit molecule or strength substitution. Compare total documented target material rather than unit count alone, especially when different molecular formats make a simple per-milligram comparison incomplete.

Match analytical packages to molecular complexity

Request identity, purity or composition and quantitative evidence suited to each exact material and production route. HPLC and mass spectrometry may be part of both packages, but methods, expected profiles and interpretation need not be identical. Check sample IDs, expected molecular information, chromatograms or profiles, method references, dates, specifications, results and authorization. A report for one GLP-1 product cannot qualify another, and one purity percentage cannot prove every structural, compositional or content attribute.

Verify content and mass basis independently

Ask how each 5mg, 10mg or 30mg claim is assigned, what tolerance applies and whether it refers to net target material or total lyophilized mass. Obtain suitable quantitative results or controlled filling records. Keep identity, purity or composition, concentration and fill quantity in separate acceptance fields. If formulation components are present, request enough information to interpret the label. A lower price per vial is not comparable until the quantity basis and evidence scope are aligned.

Control documents, storage and recurring supply

Require the batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list to agree on product, strength, unit, lot and quantity. Confirm released stock, MOQ, testing and filling lead time, shipping term and change notification. At receipt, preserve lot traceability and quarantine unexplained temperature, label, seal or quantity deviations. Review every new lot rather than extending approval from one GLP-1 product to the other.

Build one comparable wholesale RFQ matrix

Send every candidate the same fields: controlled identity, strength, vial count, total material, target purity or composition, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, MOQ, lead time and shipping term. Mark missing answers as exceptions instead of filling gaps with assumptions. Separate testing, setup, customization and transport costs from recurring unit price. A standardized matrix gives scientific, purchasing and quality reviewers one auditable record and prevents an incomplete offer from appearing cheaper simply because it describes less work.

Apply a batch-focused quality-control review

Define every required attribute, acceptance criterion, method and record before purchase. Use the quality-control framework to connect each supplier claim to evidence and its method scope. Check sample identifiers, dates, report numbers, units and lot relationships across the complete reports. Batch-specific evidence is more decision-useful than a representative certificate. Preserve original files, record revisions and investigate contradictions before approving shipment. Where risk warrants, arrange independent testing under a documented sampling and custody plan.

Create a documentation gate before dispatch

List the required batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ and purchase order. Reconcile product, strength, lot, quantity and revision across records with the documentation guide. Require replacement documents when the offered lot changes. The importer remains responsible for current destination requirements. Research-use wording improves clarity but cannot guarantee customs entry or replace destination-specific legal and broker review.

Verify supplier and batch ownership

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A trading or coordination company can work with qualified partners, but roles and accountability must be transparent. Ask who owns the batch record, authorizes release, handles deviations and provides corrective action. Require advance notification when a critical party changes. Business-registration evidence supports identity but does not replace technical qualification of the offered lot.

Plan logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject guarantees of customs clearance or misleading declarations. On receipt, document package condition, seals, product, strength, lot and quantity, then connect internal inventory to the supplier batch. Store according to the applicable approved specification and quarantine unexplained damage, label conflicts, quantity differences or excursions until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification and evidence expectations planned for wholesale scale. Assess document accuracy, packaging, delivery time, communication and corrective response. Update a supplier scorecard from observed performance rather than catalog breadth or claims. For every new lot, repeat the batch review and approve current documents before dispatch. Require notification before changes to material specification, manufacturing, testing, filling, labels, packaging or other buyer-approved conditions.

Related products and same-category guides

• Liraglutide 5mg
• Liraglutide 10mg
• Liraglutide 30mg
• Dulaglutide 5mg
• Dulaglutide 10mg
• GLP-1 Research Peptide Sourcing Guide
• Tirzepatide vs Retatrutide Guide

Frequently asked questions